Yellow Dye 5 vs Blue Dye 2: which is worse?

What is Yellow Dye 5?

Yellow Dye 5 (tartrazine) is a synthetic lemon-yellow azo dye derived from petroleum. It produces a bright, stable yellow color in acidic conditions and is one of the most widely used yellow dyes globally. Its chemical formula is C16H9N4Na3O9S2.

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

Documented risks

Yellow Dye 5: Yellow Dye 5 was one of six dyes studied in the landmark 2007 McCann et al. study in The Lancet. The study found statistically significant increases in hyperactivity in children ages 3 and 8–9 given a mixture containing tartrazine and sodium benzoate. EFSA reviewed the evidence and confirmed the effect was real, mandating the EU warning label from 2010. A 2012 review in Neurotherapeutics (Arnold et al.) confirmed that artificial food colors including tartrazine have a small but statistically significant adverse effect on children's behavior that is not confined to those with diagnosed ADHD. Tartrazine is one of the most documented causes of food dye hypersensitivity. Cross-reactivity with aspirin (acetylsalicylic acid, ASA) is well established in allergy literature: individuals with aspirin hypersensitivity have elevated risk of reacting to tartrazine. Symptoms include urticaria, angioedema, rhinitis, and in rare cases anaphylaxis. Prevalence of tartrazine sensitivity is estimated at 0.1% of the population but higher in aspirin-sensitive individuals. Because of this known hypersensitivity risk, the FDA specifically requires Yellow No. 5 to be declared by name on US food labels — an exceptional requirement not applied to most other additives, reflecting the FDA's acknowledgment of this real clinical concern. EFSA's 2009 re-evaluation found no evidence of genotoxicity in standard test systems at food use levels, setting an ADI of 7.5 mg/kg body weight, but noted in vitro evidence at higher doses. In April 2025, the FDA announced plans to phase out Yellow 5 along with other petroleum-based dyes.

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.